A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.
about
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis.Developing antigen-specific therapies in multiple sclerosis: a tale of Tantalus or Ulysses?Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby.Binding interactions between peptides and proteins of the class II major histocompatibility complex.Degeneracy, as opposed to specificity, in immunotherapy.Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blockingActive immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injuryHeteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity.Peptide-based therapeutic vaccines for allergic and autoimmune diseases.Immune modulating peptides for the treatment and suppression of multiple sclerosis.Antigen-specific inhibition of CD4(+) T-cell responses to β-lactoglobulin by its single amino acid-substituted mutant form through T-cell receptor antagonism.Association of Autophagy in the Cell Death Mediated by Dihydrotestosterone in Autoreactive T Cells Independent of Antigenic Stimulation.Immunotherapy for the prevention and treatment of type 1 diabetes.Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitisIn vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergyProphylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigenEffects of vaccination with altered Peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosisProspects for antigen-specific tolerance based therapies for the treatment of multiple sclerosisAmelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanismsTaming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen.Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region-3 of a pathogenic anti-DNA monoclonal antibody.Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide.Absence of "original antigenic sin" in autoimmunity provides an unforeseen platform for immune therapy.OSP/claudin-11-induced EAE in mice is mediated by pathogenic T cells primarily governed by OSP192Y residue of major encephalitogenic region OSP179-207.Role of inactivated influenza vaccine in regulation of autoimmune processes in experimental autoimmune encephalomyelitis.Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope.Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.Specific immunotherapy: one size does not fit all.The anergy induction of M3 muscarinic acetylcholine receptor-reactive CD4+ T cells suppresses experimental sialadenitis-like Sjögren's syndrome.DNA vaccination to treat autoimmune diabetes.
P2860
Q33180102-DBE3CE7D-0D0E-470F-8E4C-9576AC097B3AQ33528981-54C007E6-A6C1-46B6-BC78-D3512FB24940Q33546205-5B54F813-FDED-41FA-85F0-8044406D01FEQ33713307-685BCE15-0427-4474-8775-DFBC1934858FQ34119484-85D7FE4E-1F95-4177-8CFC-ABEF2EE8918DQ34380578-E8471819-515B-481A-8DB4-C07A3D4D0DA5Q34540061-84EDA8E9-CB2B-485D-92EA-E86FAB954CCBQ34551385-58889FFE-9F2E-4871-AE9E-7C5126414D53Q34567730-C9E51404-70A6-4ABC-9B84-658C5C53AE82Q34792611-F57B078E-0A65-4E6C-9B42-1D7524B80534Q34830749-4C705620-9A87-4521-BF55-2E60C1D4ED0EQ35121911-F52D9B3F-E05D-4F78-81AC-AF7DF8553279Q35675262-D756BE66-087C-41AB-8472-DFD4D96CF3EFQ36090197-720F7CF7-2573-4F3F-94F5-466688B64974Q36151968-5D5039F8-903B-4848-80C0-5B89EF7B6A05Q36304701-36B3489D-18CD-403A-B816-11BFB305052CQ36326808-746FA80F-0E9D-46A8-A4BF-D9F2D659D2B5Q36327355-7DA68216-7B41-4E6D-A98E-4D8A17E98E25Q36327367-5E17E92A-1107-4665-A6CF-465C13DF9B99Q36368042-536FDFFB-A792-416E-B880-60C7F953F4CAQ36370315-3F0811DC-EE24-483D-88C8-0FBC9557F421Q36401218-601C3850-29F2-4E45-A827-89D7E8F2BF8AQ37002699-25FA8952-BC69-4D2A-9381-6CE57653FF01Q37113532-9C7C32D0-F3E6-4DEF-AFBD-B4FA83AC7CC4Q37261686-DD99F154-2820-4FA1-B5EE-BD95580160BAQ37364480-9E1CA282-EE82-4F8C-967E-B8BBD952819CQ37415917-242A4FBF-FD0D-44B1-9D55-D884161E6BE5Q38477340-EBE4CBAE-3816-4C43-B390-A927BF43DA8EQ40862395-2C414FCA-CB28-46A8-9371-28998CFF8062Q40894906-DE87B488-8E8F-4B7F-A4D4-88B063E82467Q40897925-01B263E3-E6A3-4545-B1CC-13F730EE7BF9Q41201845-03053EF7-21D4-4513-9680-2413CD8E9016Q41643784-DC27C814-B5BC-42F2-8774-2AF10F577CB3Q42622912-8B203AB3-0A67-425D-B655-E6397DC46F8DQ43736164-2E6A6E9E-72C3-4DF4-965E-82EB05F2F8F8Q44068971-BE4BF9E8-61B3-4F0F-B305-24739B7B10A1Q45806642-E58543FA-EAD6-4A00-8A5D-DC251185B0B8Q47228169-09BB0854-166A-4839-AD2D-8D510DD3288AQ50987029-DA9495F0-C891-48FA-A002-32A0D75183AAQ52025060-0A68C4BA-8C2D-49AB-9A81-93FA7C89B8AF
P2860
A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
A T cell receptor antagonist p ...... with multiple myelin antigens.
@ast
A T cell receptor antagonist p ...... with multiple myelin antigens.
@en
type
label
A T cell receptor antagonist p ...... with multiple myelin antigens.
@ast
A T cell receptor antagonist p ...... with multiple myelin antigens.
@en
prefLabel
A T cell receptor antagonist p ...... with multiple myelin antigens.
@ast
A T cell receptor antagonist p ...... with multiple myelin antigens.
@en
P2093
P2860
P356
P1476
A T cell receptor antagonist p ...... with multiple myelin antigens.
@en
P2093
B P Hafler
L B Nicholson
V K Kuchroo
P2860
P304
P356
10.1073/PNAS.94.17.9279
P407
P577
1997-08-01T00:00:00Z